Healthcare / Drug Manufacturers - Specialty & GenericNSE
$398.80
-27.90 (-6.46%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-250.9M · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
50/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$43.5B
P/E
93.0x
↑EV/EBITDA
57.8x
↑ROE
16.2%
↑Gross Margin
83.4%
↑Debt/Equity
0.56
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+3.8%
FCF CAGR
—
FCF margin
-74.6%
FCF / Net income
-2.65x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.66B · net income $466.9M · FCF $-1.24B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.66B | $1.66B | $1.51B | $1.70B | $1.48B |
| Net Income | $466.9M | $466.9M | $487.7M | $591.6M | $579.7M |
| EBITDA | $779.6M | $779.6M | $715.5M | $835.4M | $801.4M |
| EPS | — | — | 4.48 | 5.43 | 5.32 |
| Gross Margin | 83.4% | 83.4% | 78.9% | 75.5% | 79.2% |
| Operating Margin | 37.8% | 37.8% | 42.1% | 44.5% | 49.0% |
| Net Margin | 28.2% | 28.2% | 32.3% | 34.8% | 39.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.56 | 0.56 | 0.12 | 0.01 | 0.00 |
| Current Ratio | 1.12 | 1.12 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.24B | $-1.24B | $-250.9M | $-104.3M | $157.7M |
| Returns | |||||
| ROE | 16.2% | 16.2% | 19.6% | 29.4% | 38.9% |
| Valuation | |||||
| P/E | 92.96 | 92.96 | 58.58 | — | — |
| EV/EBITDA | 57.78 | 57.78 | 40.19 | — | — |
| P/B | 15.10 | 15.10 | 11.50 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 10.0% | 10.0% | -11.2% | 14.6% | — |
| EPS Growth | — | — | -17.5% | 2.1% | — |
| Dividend Yield | 0.2% | 0.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+28.8%
Start / end P/E
n/dx → n/dx
EPS bridge
4.48 → n/d
Residual
+28.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.